Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01376089 · ClinicalTrials.gov registry record · Phase 4
Iodixanol Versus Iopamidol in Patients Undergoing Contrast-Enhanced Computed Tomographic Imaging of Abdomen/Pelvis
A Phase 4 study of Patient Comfort and Safety, sponsored by GE Healthcare.
- Completed
- Registry status
- Phase 4
- Development phase
- 304
- Enrollment target
- 1
- Study location
NCT01376089 is a Phase 4 study of Patient Comfort and Safety that has completed, run by GE Healthcare. The registered enrollment target is 304 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01376089, a Phase 4 study of Patient Comfort and Safety, has completed, sponsored by GE Healthcare.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 304 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate and compare overall patient comfort profile between the Iso-osmolar contrast media (IOCM), iodixanol 320 mg I/mL, and a Low-osmolar contrast media (LOCM), iopamidol 370 mg I/mL in patients undergoing Contrast-Enhanced Computed Tomographic (CECT) imaging of the abdomen/pelvis.
Conditions Studied
Interventions
- DRUG Iopamidol
- DRUG Iodixanol
Study Locations (1)
New Jersey
- GE Healthcare - Princeton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 304 participants |
| Start Date | 2011-05 |
| Est. Completion | 2012-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01376089
The ClinicalTrials.gov registry entry for NCT01376089 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 304 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GE Healthcare, which has 99 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Patient Comfort and Safety appearing as the primary indexed condition, and to 2 interventions - of which Iopamidol is the first listed.
NCT01376089 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT01376089 about?
NCT01376089 is a clinical study titled "Iodixanol Versus Iopamidol in Patients Undergoing Contrast-Enhanced Computed Tomographic Imaging of Abdomen/Pelvis". The purpose of this study is to evaluate and compare overall patient comfort profile between the Iso-osmolar contrast media (IOCM), iodixanol 320 mg I/mL, and a Low-osmolar contrast media (LOCM), iopamidol 370 mg I/mL in patients undergoing Contrast-Enhanced Computed Tomographic (CECT) imaging of th...
What is the current status of trial NCT01376089?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 304 participants. The study started on 2011-05. Estimated completion is 2012-02.
What conditions does trial NCT01376089 study?
This clinical trial studies the following conditions: Patient Comfort and Safety.
What interventions are being tested in trial NCT01376089?
The interventions under investigation include: Iopamidol (DRUG), Iodixanol (DRUG).
Who is sponsoring clinical trial NCT01376089?
This trial is sponsored by GE Healthcare, which has 99 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01376089 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.